NASDAQ: TWSTTwist Bioscience Corp Stock
$24.05-0.46 (-1.88%)
Updated Nov 30, 2023
TWST Price
$24.05
Fair Value Price
N/A
Market Cap
$1.39B
52 Week Low
$11.46
52 Week High
$31.51
P/E
-6.68x
P/B
2.22x
P/S
4.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$245.11M
Earnings
-$204.62M
Gross Margin
36.6%
Operating Margin
-83.01%
Profit Margin
-83.5%
Debt to Equity
0.25
Operating Cash Flow
-$142M
Beta
1.7
Next Earnings
Feb 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TWST Overview
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TWST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TWST is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TWST is good value based on its book value relative to its share price (2.22x), compared to the US Diagnostics & Research industry average (3.91x)
P/B vs Industry Valuation
TWST is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TWST due diligence checks available for Premium users.
Be the first to know about important TWST news, forecast changes, insider trades & much more!
TWST News
Valuation
TWST fair value
Fair Value of TWST stock based on Discounted Cash Flow (DCF)
Price
$24.05
Fair Value
$20.98
Overvalued by
14.63%
TWST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TWST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.68x
Industry
30.73x
Market
29.24x
TWST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.22x
Industry
3.91x
TWST is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TWST's financial health
Profit margin
Revenue
$66.9M
Net Income
-$46.2M
Profit Margin
-69.1%
TWST's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TWST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$776.4M
Liabilities
$153.0M
Debt to equity
0.25
TWST's short-term assets ($424.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TWST's short-term assets ($424.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TWST's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TWST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.7M
Investing
-$2.2M
Financing
$442.0k
TWST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TWST vs Diagnostic & Research Stocks
Twist Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.